Lupin Limited has informed the Exchange regarding a press release dated April 17, 2025, titled "Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its injectable manufacturing facility in Nagpur. An EIR is issued after the FDA concludes its inspection of a drug manufacturing site, and receiving it generally signals that the facility has met the regulator's compliance standards. This paves the way for Lupin to manufacture and supply injectable products from the Nagpur plant to the highly lucrative US market. The injectable segment is a key growth area for Indian pharma companies as it offers higher margins and lower competition compared to oral solids.
Positive for shareholders — regulatory clearance from the US FDA removes uncertainty around the facility and enables Lupin to pursue new injectable product approvals and launches in the US, which can drive future revenue and earnings growth from this site.